Free Trial
NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

CytoMed Therapeutics logo
$2.15 -0.05 (-2.27%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CytoMed Therapeutics Stock (NASDAQ:GDTC)

Key Stats

Today's Range
$2.08
$2.21
50-Day Range
$2.01
$2.42
52-Week Range
$1.20
$4.05
Volume
9,249 shs
Average Volume
78,049 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

CytoMed Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

GDTC MarketRank™: 

CytoMed Therapeutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytoMed Therapeutics has received no research coverage in the past 90 days.

  • Read more about CytoMed Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    1.20% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CytoMed Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytoMed Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.20% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    CytoMed Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for CytoMed Therapeutics this week, compared to 0 articles on an average week.
Receive GDTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GDTC Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
CytoMed Therapeutics Limited (GDTC)
See More Headlines

GDTC Stock Analysis - Frequently Asked Questions

CytoMed Therapeutics' stock was trading at $3.40 on January 1st, 2025. Since then, GDTC shares have decreased by 36.8% and is now trading at $2.15.

CytoMed Therapeutics (GDTC) raised $10 million in an initial public offering (IPO) on Friday, April 14th 2023. The company issued 2,412,369 shares at a price of $4.00 per share.

Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

Today
7/07/2025
Next Earnings (Estimated)
7/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GDTC
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+132.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50 thousand
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
3.52

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.36
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:GDTC) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners